Table 1.

Patients demographics and clinical characteristics (N = 158)

Characteristic	No. of patients, n (%)
Median age (range), y	45 (18-86)
Sex
Male	88 (55.7)
Female	70 (44.3)
Living Arrangement
Lives alone	24 (15.2)
Lives with someone	134 (84.8)
Residence
Dar es Salaam	61 (38.6)
Outside Dar es Salaam	97 (61.4)
History of CML at diagnosis
Symptomatic at diagnosis	155 (98.1)
Types of symptoms at diagnosis
Anemia	129 (81.7)
Requiring blood transfusion	52 (32.9)
Number of blood transfusions
1-3 units	36 (22.8)
4-6 units	14 (8.9)
>6 units	2 (1.2)
Abdominal fullness	136 (86.1)
Constitutional symptoms	110 (69.6)
Bleeding tendencies	34 (21.5)
Clinical signs at diagnosis
Pallor	139 (88.0)
Splenomegaly	133 (84.2)
Massive splenomegaly (≥20cm)	59 (44.2)
Hepatomegaly	27 (17.1)
Skin nodules	23 (14.6)
Lymph node enlargement	9 (5.7)
Laboratory parameters at diagnosis, median (range)
White blood cells, ×109/L	241.0 (8.0-760.0)
Hemoglobin, g/dL	7.8 (2.6-13.3)
Platelets, ×109/L	318 (67-1832)
Disease phase at diagnosis, n = 132
Chronic phase	123 (93.2)
Accelerated phase	9 (6.8)
Blast crisis	0 (0.0)
Sokal Risk groups, n = 104
Low	10 (10.0)
Intermediate	51 (49.0)
High	43 (41.0)
Hydroxyurea use prior Imatinib	101 (63.9)
Median hydroxyurea dose (range), mg	2000 (500-3000)
Duration of imatinib treatment, median (range)	32 (3-159)
<12 mo	28 (17.7)
≥12-24 mo	37 (23.4)
>24 mo	93 (58.9)
Imatinib starting dose
400 mg/d	146 (92.4)
600 mg/d	9 (5.7)
800 mg/d	3 (1.9)
Adherence to imatinib
Low (MMAS-8 score, <6)	68 (43.0)
Medium (MMAS-8 score, 6 to <8)	50 (31.7)
High (MMAS-8 score, 8)	40 (25.3)

Unless stated otherwise, data are number of patients (percentage of the total study group or the subgroup).

MMAS, Morisky Medication Adherence Scale.